Novo Nordisk to cut US list prices of two insulin products by more than 70%

 Novo Nordisk today announced plans to reduce the US list prices of two insulin products by more than 70% to better meet the needs of people living with diabetes.

The list prices of vials and pre-filled pens of insulin aspart (rapid-acting) and basal insulin (long-acting), specifically Tresiba® and Fiasp®, will be reduced in the US starting January 1, 2026. Those new list prices, also referred to as wholesale acquisition costs (WAC), will be:

Tresiba®	U-100 Vial	U-100 Device	U-200 Device
Current WAC/pkg	$338.95	$508.43	$610.11
New WAC/pkg	$94.29	$141.43	$169.71

 

Fiasp®	Vial	FlexTouch®	PenFill®	PumpCart®
Current WAC/pkg	$289.36	$558.83	$537.47	$286.65
New WAC/pkg	$72.34	$139.71	$134.37	$71.66

 

The list prices of Fiasp® will be reduced by 75%, matching the price of NovoLog®. Additionally, the list prices of Tresiba® will be reduced by 72.2%, making it 20% lower than its unbranded biologic equivalent, insulin degludec, thereby rendering the latter redundant. As such, Novo Nordisk Pharma, Inc. will discontinue the unbranded biologic versions below by December 31, 2025.

• Insulin Aspart 10 mL vial
• Insulin Aspart 3 mL PenFill^® cartridge
• Insulin Aspart 3 mL FlexPen^®
• Insulin Aspart Protamine and Insulin Aspart Mix 70/30 10 mL vial
• Insulin Aspart Protamine and Insulin Aspart Mix 70/30 3 mL FlexPen^®
• Insulin Degludec 100 units/mL (U-100) 10 mL vial
• Insulin Degludec 100 units/mL (U-100) 3 mL FlexTouch^®
• Insulin Degludec 200 units/mL (U-200) 3 mL FlexTouch^®

Novo Nordisk is making healthcare professionals, wholesalers and payers aware of the discontinuations more than 12 months in advance, so they can enable smooth transitions to other options. Patients should speak with their healthcare professional about their treatment options to determine the best course of action.

https://www.novonordisk-us.com/media/news-archive/news-details.html?id=915073